Cholera Vaccine Market Overview:
The global cholera vaccine market size in 2017 is $ 65 million, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025.
A vaccine is a biological preparation that assists in strengthening the immune system and provides acquired immunity against a specific pathogen. Vaccinations have proved to be one of the best methods to treat infectious diseases by many international organizations such as the World Health Organization (WHO). Cholera is one of the type of infectious disease caused by the bacterium Vibrio cholera. It is associated with the severe diarrhea and the immediate treatment is essential as death is inevitable if the disease is left untreated. Cholera is anticipated to be a global threat to public health especially in regions that lack social development. Thus, cholera vaccine is essential to control cholera. There are two types of cholera vaccine available in the market including inactivated and live oral cholera vaccines, whereas inactivated cholera vaccines are successfully employed globally. These vaccines are mainly taken by travelers and the people who are living in the cholera affected region. In addition, WHO is recommended that cholera vaccine should be taken at least 2 weeks before arrival at the destination and at least 1 week of gap between the doses. Hence, these aforementioned factors helps in increasing the global cholera vaccine market share.
The demand for the global cholera vaccine market is increasing due to high prevalence of chronic diseases, lack of proper sanitation & consumption of contaminated food, and growth in awareness about cholera preventive care. In addition, the development of novel approaches for new cholera vaccine and increase in government focus on immunization programs further drive the market growth. However, longer timelines required for cholera vaccine production, risk of adverse effects, high costs associated with the development of vaccines, and the time taken for the regulatory approval is projected to impede growth of the cholera vaccine market. On the contrary, high growth opportunities in untapped markets are expected to provide significant profitable opportunities for the manufacturers in the cholera vaccine industry.
Product segment review:
Based on product, the cholera vaccine market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. The Dukoral segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, owing to the established stockpile of this oral cholera vaccine by WHO. It is the only vaccine that provides protection against diarrhea caused by heat-labile-toxin-producing E. coli. In addition, growth in the number of travelers to the low- and middle-income countries (LMICs), increases the demand for Dukoral vaccine.
End user segment review:
Depending on end user, the cholera vaccine market is categorized into hospitals & clinics, research & academic laboratories, and pharmaceutical & biotechnology companies. The research & academic laboratories segment is projected to exhibit the highest growth during the forecast period. This is attributed to the rise in demand for cholera vaccine across the world. This gives immense opportunities to the researchers to use the existing vaccines and develop new cholera vaccines, which should be more effective and affordable. Thus, helps in increasing the cholera vaccine market size in the near future.
Region segment review:
Region wise, the cholera vaccine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to the increase in the prevalence of cholera disease and rise in importance of immunization. The market in North America is expected to grow at the highest CAGR during the forecast period. The U.S. market has the highest share of the market in 2017, attributable to the launch of the first and only oral cholera vaccine, Vaxchora, in the U.S. Furthermore, the number of travelers from U.S. to cholera-affected countries is increasing, thereby increasing the demand for immunization.
The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., Johnson & Johnson (Crucell), and Celldex Therapeutics, Inc. The other players in the value chain include Merck & Co., Inc., GlaxoSmithKline plc., and others.
Key Benefits For Cholera Vaccine Market:
- is report provides a detailed quantitative analysis of the current cholera vaccine market trends and cholera vaccine market forecast estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
- An in-depth cholera vaccine market analysis includes analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global cholera vaccine market is provided.
- Region-wise and country-wise cholera vaccine market conditions are comprehensively analyzed in this report.
- The projections in this report are made by analyzing the current trends and future market potential from 2018 to 2025 in terms of value.
- An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
- Key market players within the cholera vaccine market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global cholera vaccine market.
Cholera Vaccine Market Report Highlights
By End User
Key Market Players
Celldex Therapeutics, Inc., Johnson & Johnson (Crucell), Sanofi (Shantha Biotechnics Private Limited), Emergent BioSolutions, Inc. (PaxVax, Inc.), Eubiologics Co., Ltd., Astellas Pharma, Inc.
Cholera is a bacterial disease causing severe diarrhea and dehydration, usually spread via contaminated water and food. A cholera vaccine is used to prevent and immunize people from the disease. These vaccines are of two types: killed oral O1 with whole-cell with B subunit and killed oral O1 & O139. This killed vaccine is well tolerated and confers high-level (85 90%) protection for 6 months after the second immunization in all vaccines aged more than 2 years. In addition, after 3 years of immunization, the level of protection is about 50% in vaccines that were 5 years or older at the time of vaccination.
The global cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and rise in the awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players.
Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. The demand for Vaxchora is projected to exhibit the fastest market growth during the forecast period due to its advantages such as single dose immunization and reduced adverse effects.
Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the U.S. Furthermore, the number of travelers to cholera-affected countries is increasing, thereby increasing the demand for immunization.